Acumen Pharmaceuticals Dividendi e riacquisti

Dividendo criteri di controllo 0/6

Acumen Pharmaceuticals non ha registrato alcun pagamento di dividendi.

Informazioni chiave

n/a

Rendimento del dividendo

-5.3%

Rendimento del riacquisto

Rendimento totale per gli azionisti	-5.3%
Rendimento futuro dei dividendi	0%
Crescita dei dividendi	n/a
Prossima data di pagamento dei dividendi	n/a
Data di stacco del dividendo	n/a
Dividendo per azione	n/a
Rapporto di remunerazione	n/a

Aggiornamenti recenti su dividendi e riacquisti

Nessun aggiornamento

Recent updates

Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth

Sep 21

We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Feb 01

Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

Oct 16

Acumen Pharma at 11-month high on rivals’ Alzheimer’s data

Sep 28

Acumen Pharmaceuticals initiated at buy at H.C. Wainwright on Alzheimer's candidate

Jun 30

We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth

May 10

We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Jan 07

Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

Oct 01

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di ABOS siano rimasti stabili in passato.

Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di ABOS siano aumentati.

Rendimento dei dividendi rispetto al mercato

Acumen Pharmaceuticals Rendimento dei dividendi rispetto al mercato

Come si colloca il rendimento da dividendo di ABOS rispetto al mercato?
Segmento	Rendimento dei dividendi
Azienda (ABOS)	n/a
Fondo del 25% del mercato (US)	1.3%
Top 25% del mercato (US)	4.2%
Media del settore (Biotechs)	2.3%
Analista previsionale (ABOS) (fino a 3 anni)	0%

Dividendo notevole: Impossibile valutare il rendimento dei dividendi di ABOS rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Dividendo elevato: Impossibile valutare il rendimento dei dividendi di ABOS rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Distribuzione degli utili agli azionisti

Copertura degli utili: Dati insufficienti per calcolare il payout ratio di ABOS per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché ABOS non ha segnalato alcun pagamento.

Acumen Pharmaceuticals Dividendi e riacquisti

Dividendo criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti su dividendi e riacquisti

Recent updates

Price target decreased by 8.7% to US$10.80

Acumen Pharmaceuticals, Inc. Appoints Amy Schacterle as Chief Regulatory Officer and Head of Quality

Acumen Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Does Acumen Pharmaceuticals (NASDAQ:ABOS) Have A Healthy Balance Sheet?

Acumen Pharmaceuticals, Inc. Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC) 2024

Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's

Acumen Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 14, 2024

Acumen Pharmaceuticals, Inc., Annual General Meeting, Jun 04, 2024

Is Acumen Pharmaceuticals (NASDAQ:ABOS) Weighed On By Its Debt Load?

Acumen Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 26, 2024

Acumen Pharmaceuticals, Inc. Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's At the AD/PD 2024 Annual Meeting

Acumen Pharmaceuticals, Inc. Appoints James Doherty as Its President and Chief Development Officer

Price target decreased by 8.4% to US$14.00

CEO, President & Director notifies of intention to sell stock

Price target increased by 8.6% to US$16.60

Acumen Pharmaceuticals, Inc. announced that it expects to receive $50 million in funding

Acumen Pharmaceuticals, Inc. announced that it expects to receive $50 million in funding

Acumen Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Acumen Pharmaceuticals, Inc. Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer's Disease at the 16th Annual Clinical Trials on Alzheimer's Disease

Acumen Pharmaceuticals, Inc. to Present Deeper Insights from First-In-Human Phase 1 Study of ACU193 for Early Alzheimer’s During Symposium At the 16Th Annual Clinical Trials on Alzheimer’s Disease (CTAD)

Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth

Independent Director notifies of intention to sell stock

Acumen Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New minor risk - Shareholder dilution

Acumen Pharmaceuticals, Inc. Presents Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease at the Alzheimer’s Association International Conference (AAIC) 2023

Price target decreased by 8.0% to US$14.57

Acumen Pharmaceuticals Completes Enrollment in Phase 1 Trial of Acu193, First Monoclonal Antibody Developed to Selectively Target Toxic A<Beta> Oligomers in Patients with Early Alzheimer's Disease

Acumen Pharmaceuticals Provides Updates with Respect to INTERCEPT-AD

We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Acumen Pharmaceuticals Appoints Derrell Porter, M.D., to Its Board of Directors

Price target increased to US$17.20

Key Executive exercised options to buy US$273k worth of stock.

Acumen Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Acumen Pharmaceuticals, Inc. Publishes Phase 1 Trial Design and Clinical Development Plan for ACU193

Acumen Pharmaceuticals, Inc. Acu193, an Anti-Amyloid Beta Oligomer Antibody, Granted Fda Fast Track Designation for Alzheimer's Disease

Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

Price target increased to US$16.00

Acumen Pharma at 11-month high on rivals’ Alzheimer’s data

Acumen Pharmaceuticals, Inc. Announces Resignation of Dr. Jeffrey Sevigny to Its Board of Directors

Acumen Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Acumen Pharmaceuticals initiated at buy at H.C. Wainwright on Alzheimer's candidate

Acumen Pharmaceuticals, Inc.(NasdaqGS:ABOS) dropped from Russell 2500 Value Index

Acumen Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 16, 2022

We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth

Full year 2021 earnings released

Acumen Pharmaceuticals, Inc. Announces Management Changes

We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Third quarter 2021 earnings released: US$0.10 loss per share

Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

Acumen Pharmaceuticals, Inc. has completed an IPO in the amount of $159.999984 million.

Stabilità e crescita dei pagamenti

Rendimento dei dividendi rispetto al mercato

Distribuzione degli utili agli azionisti

Pagamenti in contanti agli azionisti

Scoprire le società che pagano dividendi forti